These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Selection of glycoprotein IIb/IIIa inhibitors for upstream use in patients with diabetes experiencing unstable angina or non-ST segment elevation myocardial infarction. What have we learned in the last 10 years? Silva MA; Gandhi PJ J Clin Pharm Ther; 2004 Dec; 29(6):497-510. PubMed ID: 15584937 [TBL] [Abstract][Full Text] [Related]
6. The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: a cost-effectiveness analysis. Glaser R; Glick HA; Herrmann HC; Kimmel SE J Am Coll Cardiol; 2006 Feb; 47(3):529-37. PubMed ID: 16458131 [TBL] [Abstract][Full Text] [Related]
7. Small molecule glycoprotein IIb/IIIa receptor inhibitors as upstream therapy in acute coronary syndromes: insights from the TACTICS TIMI-18 trial. Cannon CP J Am Coll Cardiol; 2003 Feb; 41(4 Suppl S):43S-48S. PubMed ID: 12644340 [TBL] [Abstract][Full Text] [Related]
8. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Eur Heart J; 1998 Apr; 19 Suppl D():D10-21. PubMed ID: 9597518 [TBL] [Abstract][Full Text] [Related]
9. Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention. Ronner E; Dykun Y; van den Brand MJ; van der Wieken LR; Simoons ML Eur Heart J; 1998 Nov; 19(11):1608-16. PubMed ID: 9857912 [No Abstract] [Full Text] [Related]
10. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors. Adgey AA Am Heart J; 1998 Apr; 135(4):S43-55. PubMed ID: 9539495 [TBL] [Abstract][Full Text] [Related]
11. Evidence for prevention of death and myocardial infarction with platelet membrane glycoprotein IIb/IIIa receptor blockade by abciximab (c7E3 Fab) among patients with unstable angina undergoing percutaneous coronary revascularization. EPIC Investigators. Evaluation of 7E3 in Preventing Ischemic Complications. Lincoff AM; Califf RM; Anderson KM; Weisman HF; Aguirre FV; Kleiman NS; Harrington RA; Topol EJ J Am Coll Cardiol; 1997 Jul; 30(1):149-56. PubMed ID: 9207636 [TBL] [Abstract][Full Text] [Related]
13. Glycoprotein IIb/IIIa receptor inhibitor use in unstable angina/non-ST-segment elevation myocardial infarction: an appropriate-use model for the emergency department. Hoekstra J J Emerg Med; 2000 Oct; 19(3 Suppl):13S-19S. PubMed ID: 11050379 [TBL] [Abstract][Full Text] [Related]
14. Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. McCollam PL; Foster DA; Riesmeyer JS Am J Health Syst Pharm; 2003 Jun; 60(12):1251-6. PubMed ID: 12845921 [TBL] [Abstract][Full Text] [Related]
15. GP IIb/IIIa inhibitors: an evidence-based approach to their use. Med Manag Netw; 1999 Mar; 7(3):5-9. PubMed ID: 10346546 [No Abstract] [Full Text] [Related]
20. Pharmacodynamic and clinical trials of glycoprotein IIb/IIIa inhibitors and potential relationship of results to dosing. Hobbach HP; Schuster P Z Kardiol; 2003 Mar; 92(3):213-8. PubMed ID: 12658467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]